Helicobacter pylori infection – new approaches to a growing problem

The treatment of the bacterium Helicobacter pylori, which colonizes the human stomach, has long been considered a medical success story. For decades, the infection could be reliably treated with a two-week course of antibiotics. For many gastroenterologists, the issue seemed to be settled. However, this former success no longer corresponds to today’s clinical reality. In this article, you will learn why we are losing ground with Helicobacter pylori and what new integrative approaches can achieve.

One of the most common infections in the world – with serious consequences

Helicobacter pylori (H. pylori) is a widespread, spiral-shaped bacterium that can cause inflammation of the stomach lining (gastritis), stomach ulcers, and stomach cancer. It is adapted to aggressive stomach acid and is usually transmitted through close contact between people (often during childhood). Today, about one in two people worldwide is infected with H. pylori. Even though the percentage has declined slightly in recent decades, in absolute terms this still means that over four billion people are affected. Most people do not notice anything for a long time – but the possible consequences are serious:

• 10–20% of those infected develop a stomach ulcer (gastric ulcer) during their lifetime.
• The risk of stomach cancer is significantly increased.
• Since 1994, the World Health Organization has classified H. pylori as a carcinogen in the highest risk category—the same category as tobacco smoke and asbestos.

Stomach cancer is one of the most common causes of cancer-related deaths worldwide. If H. pylori is successfully eliminated, the risk of stomach cancer can be almost halved. The fact that hundreds of thousands of people still die from this preventable disease every year shows that we have a structural problem.

When antibiotics lose their reliability

The main reason for this is increasing antibiotic resistance. Traditional therapies, which used to achieve cure rates of over 90%, are now failing more and more often:

• In many European regions, over 20% of H. pylori strains are resistant to clarithromycin
• In parts of southern and eastern Europe, resistance is even approaching 40%.
• Metronidazole is also becoming increasingly less effective

Various recent studies show that classic triple therapy often fails in patients with antibiotic-resistant Helicobacter pylori strains, e.g., https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0265322

Side effects as an additional hurdle

Added to this are the side effects of antibiotic therapy. Between 20 and 40% of patients suffer from diarrhea, nausea, flatulence, or taste disturbances. It is not uncommon for therapies to be discontinued prematurely as a result. Another aspect is increasingly coming into focus: antibiotics have a massive impact on the gut microbiome, throwing the bacterial balance out of kilter. In most cases, it recovers, but this takes months – and in some people, long-term changes remain.

The combination of declining effectiveness, far-reaching side effects, and high disease burden has led to a rethink: away from a pure “antibiotic strategy” and toward complementary, integrative approaches.

Probiotic support with multiple strains

Probiotics are now the most widely studied adjunctive therapy for H. pylori. The data is impressive: over 200 controlled studies involving more than 50,000 patients show a consistent picture.

What are the specific benefits of probiotics?

• The success rate of eradication (destruction of the germ) increases by about 10–14 percent
• Antibiotic-related side effects decrease by 40–60 percent

At first glance, these effects may seem moderate. However, when applied to an infection that affects billions of people, they are clinically highly relevant.

How do probiotics work?

Probiotic bacteria attack H. pylori on several levels:

1. Creating an unfavorable environment
   They produce organic acids such as lactic acid, which inhibit the growth of H. pylori.
2. Preventing adhesion
   Certain strains block the pathogen’s ability to attach itself to the stomach lining.
3. Reducing inflammation
   Probiotics modulate the immune system and reduce the chronic inflammatory response, which can contribute to mucosal damage and cancer in the long term.
4. Release of bactericidal substances
   Probiotics produce substances that inhibit the growth of Helicobacter pylori or kill the bacteria directly.

The administration of probiotics can further reduce the side effects of antibiotic therapy. They stabilize the intestinal microbiome and, in particular, significantly reduce the risk of antibiotic-associated diarrhea. Studies show that multi-strain preparations are superior to single strains—especially combinations of Lactobacillus and Bifidobacterium species, e.g., https://pmc.ncbi.nlm.nih.gov/articles/PMC4971786/

The table shows the results of a preparation with 13 strains (Probiotic Vida) and the corresponding evidence regarding its effect on H. pylori.

Strain	Evidence
Lactobacillus acidophilus	Strong
Lactobacillus rhamnosus	Strong
Lactobacillus plantarum	strong
Lactobacillus casei	strong
Bifidobacterium longum	Moderate
Bifidobacterium bifidum	Moderate
Bifidobacterium infantis	moderate
Bifidobacterium breve	moderate
Bifidobacterium animalis ssp. lactis	moderate
Streptococcus thermophilus	Moderate
Lactococcus lactis	limited
Bacillus coagulans	limited
Bacillus subtilis	limited

Learn more about probiotics in our Wirstoff text

Artemisia annua: Antimicrobial support

Artemisia annua is best known for the substance it contains, artemisinin, one of the most important active ingredients against malaria. However, Artemisia contains countless other active ingredients. In recent years, it has been shown that the plant’s ingredients are also effective against viruses and bacteria, even against antibiotic-resistant strains. The data on H. pylori has so far been derived mainly from preclinical research. Nevertheless, these results provide a plausible supplement to existing therapies – with a mechanism of action that clearly differs from classic antibiotics.

This is how Artemisia annua works against H. pylori:

1. Inhibition of bacterial growth by destroying bacterial cell walls
2. Dissolving biofilms, which are often responsible for treatment failure
3. Inhibition of bacterial adhesion to the gastric epithelium

Learn more about Artemisia annua

Clinoptilolite: Physical support in the stomach

Another component of integrative concepts is clinoptilolite, a natural mineral (volcanic earth) from the zeolite group. It acts physically rather than pharmacologically.

H. pylori produces ammonia to neutralize aggressive stomach acid and survive. Clinoptilolite can bind this ammonia, thereby weakening the bacterium’s protective strategy. In addition, it adsorbs bacterial toxins and supports the mucous membrane. Although there are no direct clinical studies specifically on H. pylori, studies on other gastrointestinal diseases show good tolerability and indications of a supportive effect. It is important to use a high-quality, ultrafine clinoptilolite preparation with the perfect particle size.

The mechanism of clinoptilolite: Binding the bacterial ammonia protective layer:

Learn more about clinoptilolite in our active ingredient text

Conclusion: Away from single solutions, toward a strategy

The days of simple “one pill solves everything” therapy for H. pylori are over. Increasing resistance shows that we are dealing with a highly adaptable pathogen.

An integrative approach that combines different mechanisms therefore seems logical:

• Probiotics to stabilize the microbial balance and reduce inflammation
• Herbal active ingredients such as Artemisia, which act independently of classic resistance mechanisms
• Physical support agents ( ) such as clinoptilolite, which deprive the bacteria of their basis for survival

Instead of attacking the pathogen head-on, its entire “support system” is weakened. For an infection that causes millions of serious illnesses worldwide, this strategic combination could be crucial. The active ingredients complement each other and reinforce each other’s effects. The combination of biological modulation, chemical toxicity, and physical adsorption creates a multimodal approach that fights the pathogen on several fronts simultaneously.

Dosage recommendations

Multi-strain probiotic: According to package instructions, 1x daily on an empty stomach

Artemisia annua: 4 x 1200 mg (in capsule form), 30-60 minutes before meals & at night

Clinoptilolite: 3 x 2 capsules or 3 x 1 teaspoon of powder: 30–60 minutes before meals with 2–3 dl of water

References/studies

1. Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection:
   Systematic review and meta-analysis. Gastroenterology. 2017;153(2):420-429. PMID:
2. https://doi.org/10.1053/j.gastro.2017.04.022
3. Li Y, Choi H, Leung K, et al. Global prevalence of Helicobacter pylori infection between 1980
   and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol.
   2023;8(6):553-564. PMID: 37086739. https://doi.org/10.1016/S2468-1253(23)00070-5
4. Ebell MH. Peptic ulcer disease. Am Fam Physician. 1992;46(1):217-227. PMID: 1621633.
5. Wroblewski LE, Peek RM, Wilson KT. Helicobacter pylori and gastric cancer: factors influencing
   disease risk. Clin Microbiol Rev. 2010;23(4):713-739. PMID: 20930071.
   https://doi.org/10.1128/CMR.00011-10
6. Global prevalence of Helicobacter pylori infection and incidence of gastric cancer.
   https://doi.org/10.1053/j.gastro.2023.12.022
7. Poorolajal J, Moradi L, Mohammadi Y, et al. Risk factors for gastric cancer: a systematic
   review and meta-analysis. Epidemiol Health. 2020;42:e2020004. PMID: 32023777.
   https://doi.org/10.4178/epih.e2020004
8. Chen YC, Malfertheiner P, Yu HT, et al. Global prevalence of Helicobacter pylori infection and
   incidence of gastric cancer between 1980 and 2022. Gastroenterology. 2024;166(4):605-619.
   PMID: 38176Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy for
   preventing gastric cancer: systematic review and meta-analysis. Gut.
   2020;69(12):2113-2121. PMID: 32205420. https://doi.org/10.1136/gutjnl-2020-320839
   15
9. Megraud F, Bruyndonckx R, Coenen S, et al. Helicobacter pylori resistance to antibiotics in
   Europe in 2018 and its association with antibiotic consumption in the population.
   Gut. 2021;70(10):1815-1822. PMID: 33837118. https://doi.org/10.1136/gutjnl-2021-324032
10. Lopo I, Libânio D, Pita I, et al. Helicobacter pylori antibiotic resistance in Portugal:
    Systematic review and meta-analysis. Helicobacter. 2018;23(4):e12493. PMID: 29911329.
    https://doi.org/10.1111/hel.12493
11. Bujanda L, Nyssen OP, Ramos J, et al. Efficacy of Helicobacter pylori treatments in
    depending on antibiotic resistance. Am J Gastroenterol. 2024;119(4):646-654. PMID:
12. https://doi.org/10.14309/ajg.0000000000002600
13. Chey WD, Mégraud F, Laine L, et al. Vonoprazan triple and dual therapy for Helicobacter
    pylori infections in the United States and Europe: randomized clinical trial.
    Gastroenterology. 2022;163(3):608-619. PMID: 35679950.
    https://doi.org/10.1053/j.gastro.2022.05.055
14. Nyssen OP, McNicholl AG, Megraud F, et al. Sequential versus standard triple
    first-line therapy for eradication of Helicobacter pylori. Cochrane Database Syst Rev.
    2016;2016(6):CD009034. PMID: 27351542. https://doi.org/10.1002/14651858.CD009034.pub2
15. Gisbert JP. Helicobacter pylori-related diseases. Gastroenterol Hepatol. 2016;39 Suppl
    1:36-46. PMID: 27888863. https://doi.org/10.1016/S0210-5705(16)30173-X
16. Wang B, Lv ZF, Wang YH, et al. Standard triple therapy for Helicobacter pylori infections
    in China: a meta-analysis. World J Gastroenterol. 2014;20(40):14973-14985. PMID: 25356059.
    https://doi.org/10.3748/wjg.v20.i40.14973
17. He C, Xie Y, Zhu Y, et al. Probiotics modulate the gastrointestinal microbiota after
    eradication of Helicobacter pylori: A multicenter randomized double-blind
    placebo-controlled trial. Front Immunol. 2022;13:1033063. PMID: 36426355.
    https://doi.org/10.3389/fimmu.2022.1033063
18. Guo Y, Zhang Y, Gerhard M, et al. Effect of Helicobacter pylori on the gastrointestinal
    microbiota: a population-based study in Linqu, a high-risk area for
    stomach cancer risk. Gut. 2020;69(9):1598-1607. PMID: 31857433. https://doi.org/10.1136/gutjnl-
    2019-319696
19. Gotoda T, Takano C, Kusano C, et al. The gut microbiota can be restored after Helicobacter pylori
    eradication therapy in adolescents without side effects.
    Helicobacter. 2018;23(6):e12541. PMID: 30311721. https://doi.org/10.1111/hel.12541
20. Zhang MM, et al. Probiotics in Helicobacter pylori eradication therapy: a systematic
    review and meta-analysis. World J Gastroenterol. 2015;21(14):4345-57. PMID: 25892886.
    https://doi.org/10.3748/wjg.v21.i14.4345
21. Wang F, et al. Probiotics in Helicobacter pylori eradication therapy: systematic
    review and network meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(4):466-475.
    PMID: 28552432. https://doi.org/10.1016/j.clinre.2017.04.004
22. Zhu R, et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori
    eradication therapy. World J Gastroenterol. 2014;20(47):18013-21. PMID: 25548501.
    https://doi.org/10.3748/wjg.v20.i47.18013
23. Lü M, et al. Efficacy of probiotic supplementation therapy for the eradication of
    Helicobacter pylori: A meta-analysis of randomized controlled trials. PLoS One.
    2016;11(10):e0163743. PMID: 27723762. https://doi.org/10.1371/journal.pone.0163743
24. Westerik N, et al. The probiotic Lactobacillus rhamnosus for the relief of Helicobacter
    pylori-associated gastric disorders in East Africa. Front Microbiol. 2018;9:1873. PMID:
25. https://doi.org/10.3389/fmicb.2018.01873
26. Peng Y, et al. Lactobacillus reuteri in digestive system diseases: Focus on
    clinical trials and mechanisms. Front Cell Infect Microbiol. 2023;13:1254198. PMID:
27. https://doi.org/10.3389/fcimb.2023.1254198
28. Midolo PD, et al. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids
    and lactic acid bacteria. J Appl Bacteriol. 1995;79(4):475-9. PMID: 7592140.
    https://doi.org/10.1111/j.1365-2672.1995.tb03164.x
29. Song H, et al. Probiotic effect on the adhesion of Helicobacter pylori and inhibition
    of inflammation in human gastric epithelial cells. Exp Ther Med. 2019;18(3):1551-1562.
    PMID: 31410109. https://doi.org/10.3892/etm.2019.7742
    16
30. Do AD, et al. Lactobacillus rhamnosus JB3 inhibits Helicobacter pylori infection through
    multiple molecular effects. Helicobacter. 2021;26(3):e12806. PMID: 33843101.
    https://doi.org/10.1111/hel.12806
31. Lee JS, et al. Anti-inflammatory effect of probiotics through activation of expression
    and signaling of suppressors of cytokine signaling (SOCS) in
    Helicobacter pylori infections: a novel mechanism. J Gastroenterol Hepatol.
    2010;25(1):194-202. PMID: 20136974. https://doi.org/10.1111/j.1440-1746.2009.06127.x
32. Techo S, et al. Characterization and antibacterial activity against Helicobacter pylori of
    lactic acid bacteria isolated from Thai fermented rice noodles. Probiotics
    Antimicrob Proteins. 2019;11(1):92-102. PMID: 29362990. https://doi.org/10.1007/s12602-018-
    9385-z
33. Zhou BG, et al. Saccharomyces boulardii as an adjunctive therapy for the eradication of Helicobacter
    pylori: A systematic review and meta-analysis with sequential analysis of studies.
    Helicobacter. 2019;24(5):e12651. PMID: 31414551. https://doi.org/10.1111/hel.12651
34. Wang Y, et al. Comparative efficacy of different probiotic
    dietary supplements for triple eradication of Helicobacter pylori: a network
    meta-analysis. Front Cell Infect Microbiol. 2023;13:1120789. PMID: 37256113.
    https://doi.org/10.3389/fcimb.2023.1120789
35. McFarland LV, et al. Systematic review and meta-analysis: probiotics with multiple
    strains as adjunctive therapy for Helicobacter pylori eradication and prevention of
    adverse events. United European Gastroenterol J. 2016;4(4):546-61. PMID:
36. https://doi.org/10.1177/2050640615617358
37. Musazadeh V, et al. The effectiveness of probiotic treatment in the eradication of
    Helicobacter pylori: results of a meta-analysis of meta-analyses
    randomized controlled trials. Food Funct. 2023;14(16):7654-7662. PMID: 37540067.
    https://doi.org/10.1039/d3fo00300k
38. Shi X, et al. Efficacy and safety of probiotics in the eradication of Helicobacter
    pylori: A network meta-analysis. Medicine. 2019;98(15):e15180. PMID: 30985706.
    https://doi.org/10.1097/MD.0000000000015180
39. Zhang J, et al. The efficacy and safety of Clostridium butyricum and Bacillus coagulans
    in the treatment for eradication of Helicobacter pylori: An open-label, single-arm pilot study.
    Medicine. 2020;99(45):e22976. PMID: 33157939.
    https://doi.org/10.1097/MD.0000000000022976
40. Pourmasoumi M, et al. The effect of synbiotics in improving the eradication of
    Helicobacter pylori: A systematic review and meta-analysis. Complement Ther Med.
    2019;43:36-43. PMID: 30935552. https://doi.org/10.1016/j.ctim.2019.01.005
41. Malfertheiner P, et al. Management of Helicobacter pylori infection – the Maastricht
    IV/Florence Consensus Report. Gut. 2012;61(5):646-64. PMID: 22491499.
    https://doi.org/10.1136/gutjnl-2012-302084
42. Viazis N, et al. A four-probiotic therapy in combination with standard treatment for
    eradication of Helicobacter pylori reduces side effects and increases
    eradication rates. Nutrients. 2022;14(3):632. PMID: 35276991.
    https://doi.org/10.3390/nu14030632
43. Hauser G, et al. Probiotics for standard triple Helicobacter pylori eradication: a
    randomized, double-blind, placebo-controlled trial. Medicine. 2015;94(17):e685. PMID:
44. https://doi.org/10.1097/MD.0000000000000685
45. Guillemard E, et al. A randomized, controlled trial: effect of a fermented milk
    on the recovery of the gut microbiota after Helicobacter pylori
    therapy. Nutrients. 2021;13(9):3171. PMID: 34579049. https://doi.org/10.3390/nu13093171
46. Feng JR, et al. Efficacy and safety of triple therapy supplemented with probiotics for
    eradication of Helicobacter pylori in children: a systematic review and network
    meta-analysis. Eur J Clin Pharmacol. 2017;73(10):1199-1208. PMID: 28681177.
    https://doi.org/10.1007/s00228-017-2291-6
47. Liu LH, et al. The effect of Saccharomyces boulardii supplementation on the
    eradication of Helicobacter pylori in children: a systematic review and
    meta-analysis of randomized controlled trials. BMC Infect Dis. 2023;23(1):878. PMID:
48. https://doi.org/10.1186/s12879-023-08896-4
    17
49. P. Khanal, “Antimalarial and anticancer properties of artesunate and other
    artemisinins: current developments,” Monatsh. Chem., vol. 152, no. 4, pp. 387–400, 2021.
    PMID: 33814617. https://doi.org/10.1007/s00706-021-02759-x
50. S. Goswami, R. S. Bhakuni, A. Chinniah, A. Pal, S. K. Kar, and P. K. Das, “Anti-Helicobacter pylori
    potential of artemisinin and its derivatives,” Antimicrob. Agents Chemother., vol. 56, no.
    9, pp. 4594–4607, 2012. PMID: 22687518. https://doi.org/10.1128/AAC.00407-12
51. T. Su et al., “Artemisinin and its derivatives prevent Helicobacter pylori-induced
    gastric carcinogenesis by inhibiting NF-κB signaling,” Phytomedicine, vol. 63,
    p. 152968, 2019. PMID: 31280140. https://doi.org/10.1016/j.phymed.2019.152968
52. F. Sisto et al., “In vitro activity of artemison and artemisinin derivatives against extracellular
    and intracellular Helicobacter pylori,” Int. J. Antimicrob. Agents, vol. 48, no. 1, pp. 101–105, 2016.
    PMID: 27216383. https://doi.org/10.1016/j.ijantimicag.2016.03.018
53. F. Sisto et al., “In vitro activity of arylaminoartemisinin GC012 against Helicobacter pylori and
    its effects on biofilms,” Pathogens, vol. 11, no. 7, p. 740, 2022. PMID: 35889986.
    https://doi.org/10.3390/pathogens11070740
54. C. Le-Tien, L. Blemur, and D. Baltzis, “Artesunate dry emulsion formulation in combination
    with antibiotics for the treatment of Helicobacter pylori infections: in vitro/in vivo
    evaluation,” Int. J. Mol. Sci., vol. 24, no. 13, p. 11008, 2023. PMID: 37446184.
    https://doi.org/10.3390/ijms241311008
55. J. F. Palacios-Espinosa et al., “Anti-Helicobacter pylori activity of Artemisia ludoviciana
    subsp. mexicana and two of its bioactive components, estafiatin and eupatilin,” Molecules,
    Vol. 26, No. 12, p. 3654, 2021. PMID: 34203927. https://doi.org/10.3390/molecules26123654
56. M. Villalva et al., “Antioxidant, anti-inflammatory, and antibacterial properties of
    Achillea millefolium L. extract and its fractions obtained by supercritical
    antisolvent fractionation against Helicobacter pylori,” Antioxidants, vol. 11,
    No. 10, p. 1849, 2022. PMID: 36290572. https://doi.org/10.3390/antiox11101849
57. C. Zheng et al., “Alleviation of Helicobacter pylori-induced gastric damage by
    Artemisia argyi folium total extract, its total flavonoids, and eupatilin by
    suppression of NF-κB signaling and virulence factors,” J. Ethnopharmacol., vol.
    357, p. 120945, 2025. PMID: 41275937. https://doi.org/10.1016/j.jep.2025.120945
58. M. Jeong et al., “Dietary Intervention of Artemisia and Green Tea Extracts to Rejuvenate
    Helicobacter pylori-Associated Chronic Atrophic Gastritis and to Prevent Tumorigenesis”
    (Dietary intervention with Artemisia and green tea extracts to rejuvenate
    Helicobacter pylori-associated chronic atrophic gastritis and to prevent
    tumorigenesis), Helicobacter, vol. 21, no. 1, pp. 40–59, 2015. PMID: 25864522.
    https://doi.org/10.1111/hel.12229
59. N. Pandey and S. Pandey-Rai, “Recent developments in artemisinin: An insight into its mode of action and
    strategies for increasing global production,” Protoplasma, vol. 253, no. 1, pp. 15–30,
60. PMID: 25813833. https://doi.org/10.1007/s00709-015-0805-6
61. S. Kraljević Pavelić et al., “Critical review of the safety and medical
    applications of zeolite clinoptilolite,” Front. Pharmacol., vol. 9, p. 1350, 2018. PMID:
62. https://doi.org/10.3389/fphar.2018.01350
63. S. Panaiotov et al., “Zeolite and neurodegenerative diseases,” Molecules, vol. 29, no. 11, p.
    2614, 2024. PMID: 38893490. https://doi.org/10.3390/molecules29112614
64. G. Cerri et al., “Antibacterial effect of zinc-loaded Cuban zeolite against
    Helicobacter pylori compared to its sodium-loaded and unmodified
    counterparts,” Environ. Geochem. Health, vol. 43, no. 5, pp. 2037–2048, 2021. PMID: 33244649.
    https://doi.org/10.1007/s10653-020-00781-2
65. G. Cerri et al., “Ag and Zn clinoptilolite: a comparison of their in vitro antibacterial activity
    against Helicobacter pylori,” Environ. Geochem. Health, vol. 47, no. 12, p. 546, 2025. PMID:
66. https://doi.org/10.1007/s10653-025-02868-0
67. K. Samekova et al., “Simultaneous oral intake of purified clinoptilolite tuff (GPUR)
    reduces enteral lead uptake in healthy humans,” Sci. Rep., vol. 11, no. 1, p.
    14796, 2021. PMID: 34285282. https://doi.org/10.1038/s41598-021-94245-x
68. J. Raj et al., “Effects of modified clinoptilolite zeolite on
    growth performance, health status, and detoxification of aflatoxin B₁ and
    18
    ochratoxin A in male broiler chickens,” Br. Poult. Sci., vol. 62, no. 4, pp. 601–610, 2021. PMID:
69. https://doi.org/10.1080/00071668.2021.1891522
70. S.P. Hernández-Martínez et al., “Aluminum silicates as a double-edged sword: adsorption of
    aflatoxin B₁ and sequestration of essential trace elements in an in vitro gastrointestinal
    model for poultry,” Toxins, vol. 15, no. 9, p. 519, 2023. PMID: 37755945.
    https://doi.org/10.3390/toxins15090519
71. C. Ranftler et al., “Purified clinoptilolite tuff as an efficient sorbent for
    food-derived peanut allergens,” Int. J. Mol. Sci., vol. 25, no. 12, p. 6510, 2024.
    PMID: 38928222. https://doi.org/10.3390/ijms25126510
72. A.R. Elmore et al., “Final report on the safety assessment of aluminum silicate,
    calcium silicate … and zeolite,” Int. J. Toxicol., vol. 22, suppl. 1, pp. 37–102, 2003. PMID: 12851164.
73. K. Anderle et al., “Safety and Efficacy of Treatment with Purified Clinoptilolite
    tuff in patients with irritable bowel syndrome with diarrhea: randomized controlled trial,”
    World J. Gastroenterol., vol. 28, no. 46, pp. 6573–6588, 2022. PMID: 36569277.
    https://doi.org/10.3748/wjg.v28.i46.6573
74. T. Langbein et al., “Efficacy of Detoxsan powder in diarrhea due to gastrointestinal
    neuroendocrine tumors,” World J. Gastroenterol., vol. 25, no. 17, pp. 2133–2143, 2019. PMID:
75. https://doi.org/10.3748/wjg.v25.i17.2133
76. S. Nizet et al., “Clinoptilolite in dextran sulfate sodium-induced colitis in mice:
    Efficacy and safety of a microparticulate preparation,” Inflamm. Bowel Dis., vol. 24,
    no. 1, pp. 54–66, 2018. PMID: 29272495. https://doi.org/10.1093/ibd/izx042
77. S. Kraljević Pavelić et al., “Clinical evaluation of a defined zeolite clinoptilolite
    supplementation on selected blood parameters of patients,” Front. Med., vol. 9, pp.
    851782, 2022. PMID: 35712111. https://doi.org/10.3389/fmed.2022.851782